%0 Journal Article
%T Cardiac Agents during Neonatal Cardiopulmonary Resuscitation.
%A Ramsie M
%A Cheung PY
%A O'Reilly M
%A Roberts CT
%A Polglase GR
%A Schmölzer GM
%J Neonatology
%V 121
%N 2
%D 2024 Jan 16
%M 38228124
%F 5.106
%R 10.1159/000535502
%X <B>BACKGROUND: </B>Epinephrine (adrenaline) is currently the only cardiac agent recommended during neonatal resuscitation. The inability to predict which newborns are at risk of requiring resuscitative efforts at birth has prevented the collection of large, high-quality human data.<BR><B>CONCLUSIONS: </B>Information on the optimal dosage and route of epinephrine administration is extrapolated from neonatal animal studies and human adult and pediatric studies. Adult resuscitation guidelines have previously recommended vasopressin use; however, neonatal studies needed to create guidelines are lacking. A review of the literature demonstrates conflicting results regarding epinephrine efficacy through various routes of access as well as vasopressin during asystolic cardiac arrest in animal models. Vasopressin appears to improve hemodynamic and post-resuscitation outcomes compared to epinephrine in asystolic cardiac arrest animal models.<BR><B>CONCLUSIONS: </B>The current neonatal resuscitation guidelines recommend epinephrine be primarily given via the intravenous or intraosseous route, with the endotracheal route as an alternative if these routes are not feasible or unsuccessful. The intravenous or intraosseous dose ranges between 0.01 and 0.03 mg/kg, which should be repeated every 3-5 min during chest compressions. However, the optimal dosing and route of administration of epinephrine remain unknown. There is evidence from adult and pediatric studies that vasopressin might be an alternative to epinephrine; however, the neonatal data are scarce.